|
ZA200603619B
(en)
|
2003-11-06 |
2008-10-29 |
Seattle Genetics Inc |
Monomethylvaline compounds capable of conjugation to ligands
|
|
EP1817336B1
(en)
|
2004-11-12 |
2019-01-09 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the n terminus
|
|
US7750116B1
(en)
*
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
US8455622B2
(en)
|
2006-12-01 |
2013-06-04 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
|
AU2008230795B2
(en)
|
2007-03-27 |
2014-05-29 |
Bioassets, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
|
WO2009012256A1
(en)
|
2007-07-16 |
2009-01-22 |
Genentech, Inc. |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
|
PL2474557T3
(pl)
|
2007-07-16 |
2015-02-27 |
Genentech Inc |
Przeciwciała anty- CD79b i immunokoniugaty i sposoby stosowania
|
|
AU2008311815B2
(en)
|
2007-10-19 |
2014-02-06 |
Seagen Inc. |
CD19 binding agents and uses thereof
|
|
NZ587132A
(en)
|
2008-01-31 |
2012-10-26 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
AU2009242453B2
(en)
|
2008-05-02 |
2014-12-04 |
Seagen Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
AU2010249046A1
(en)
|
2009-05-13 |
2011-12-01 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
|
PH12012500665B1
(en)
|
2009-10-23 |
2019-10-30 |
Amgen British Columbia |
Anti-gcc antibody molecules and related compositions and methods
|
|
EP2533804B1
(en)
*
|
2010-02-08 |
2018-04-11 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to 161p2f10b proteins
|
|
EP2542576B1
(en)
*
|
2010-03-02 |
2016-04-20 |
Seattle Genetics, Inc. |
Methods for screening antibodies
|
|
EP2409712A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
|
|
EP2409993A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC function with improved glycosylation profile
|
|
CN103402525B
(zh)
|
2010-08-05 |
2017-03-01 |
西雅图基因公司 |
使用岩藻糖类似物在体内抑制蛋白质岩藻糖基化的方法
|
|
WO2012046745A1
(ja)
*
|
2010-10-04 |
2012-04-12 |
独立行政法人理化学研究所 |
Ｍｈｃクラスｉｉを発現する悪性腫瘍の治療薬
|
|
EP3581206B8
(en)
|
2010-10-22 |
2025-02-19 |
Seagen Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
|
|
SI2654780T1
(sl)
|
2010-12-23 |
2017-06-30 |
Janssen Biotech Inc. |
Aktivni proteazno rezistentni protitelesni mutanti Fc
|
|
JP5721858B2
(ja)
|
2010-12-23 |
2015-05-20 |
ユーリタ アクチエンゲゼルシャフトＥｕｌｉｔｈａ Ａｇ |
大きな面積にわたってナノ構造を製造するためのシステムおよび方法
|
|
KR101783529B1
(ko)
*
|
2011-04-01 |
2017-09-29 |
와이어쓰 엘엘씨 |
항체-약물 접합체
|
|
MX2013014583A
(es)
|
2011-06-10 |
2014-03-31 |
Mersana Therapeutics Inc |
Conjugados de proteina-polimero-farmaco.
|
|
EP2736928B1
(en)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Sur-binding proteins against erbb3
|
|
CA3137321A1
(en)
|
2011-08-16 |
2013-02-21 |
Morphosys Ag |
Combination therapy with an anti - cd19 antibody and a nitrogen mustard
|
|
MX353589B
(es)
|
2011-08-16 |
2018-01-19 |
Morphosys Ag |
Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina.
|
|
CN102343083A
(zh)
*
|
2011-10-17 |
2012-02-08 |
中国科学院成都生物研究所 |
一种抗病毒的组合药物
|
|
WO2013067581A1
(en)
*
|
2011-11-09 |
2013-05-16 |
Children's Cancer Institute Australia for Medical Research |
Cancer treatment
|
|
EP2793940B1
(en)
|
2011-12-22 |
2018-11-14 |
i2 Pharmaceuticals, Inc. |
Surrogate binding proteins
|
|
US20150011736A1
(en)
|
2012-01-20 |
2015-01-08 |
Sea Lane Biotechnologies, Llc |
Binding molecule conjugates
|
|
AU2013216863B2
(en)
|
2012-02-10 |
2018-09-06 |
Seagen Inc. |
Detection and treatment of CD30+ cancers
|
|
CN104822656B
(zh)
|
2012-05-15 |
2018-05-01 |
西雅图基因公司 |
自稳定接头偶联物
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
|
EP2872161B1
(en)
|
2012-06-26 |
2020-12-16 |
Del Mar Pharmaceuticals |
Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
|
|
AU2013289970A1
(en)
*
|
2012-07-13 |
2015-01-22 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for regulating CAR T cells
|
|
SI2692865T1
(sl)
|
2012-07-30 |
2015-03-31 |
Nbe-Therapeutics Llc Technology Parc Basel |
S transpozicijo posredovana identifikacija specifičnih vezavnih ali funkcionalnih proteinov
|
|
US10350228B2
(en)
|
2012-08-23 |
2019-07-16 |
Seattle Genetics, Inc. |
Treatment of sickle cell disease and inflammatory conditions
|
|
PL2888283T3
(pl)
|
2012-08-24 |
2019-03-29 |
The Regents Of The University Of California |
Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
|
|
CA2941485C
(en)
|
2012-10-12 |
2018-06-12 |
Philip Wilson Howard |
Pyrrolobenzodiazepines and conjugates thereof
|
|
NO2789793T3
(enExample)
*
|
2012-10-24 |
2018-01-27 |
|
|
|
SG11201501618WA
(en)
|
2012-10-24 |
2015-04-29 |
Polytherics Ltd |
Drug-protein conjugates
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
WO2014093379A1
(en)
|
2012-12-10 |
2014-06-19 |
Mersana Therapeutics, Inc. |
Auristatin compounds and conjugates thereof
|
|
WO2014100740A1
(en)
|
2012-12-21 |
2014-06-26 |
Seattle Genetics, Inc. |
Anti-ntb-a antibodies and related compositions and methods
|
|
AU2014230735B2
(en)
|
2013-03-13 |
2018-03-15 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2014151649A1
(en)
*
|
2013-03-15 |
2014-09-25 |
Alper Biotech, Llc |
Monoclonal antibodies to egfr, and uses therefor
|
|
EP2777714A1
(en)
|
2013-03-15 |
2014-09-17 |
NBE-Therapeutics LLC |
Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
|
|
TWI654206B
(zh)
*
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
AU2014251038A1
(en)
|
2013-04-08 |
2015-11-26 |
Dennis M. Brown |
Therapeutic benefit of suboptimally administered chemical compounds
|
|
HRP20240576T1
(hr)
*
|
2013-05-13 |
2024-07-19 |
Cellectis |
Cd19 specifični kimerni antigenski receptor i njegova upotreba
|
|
SI3057585T1
(sl)
|
2013-10-15 |
2020-12-31 |
Seagen Inc. |
Pegilirani linkerji zdravila za izboljšano farmakokinetiko konjugata ligand-zdravilo
|
|
US9988420B2
(en)
|
2013-12-17 |
2018-06-05 |
Novartis Ag |
Cytotoxic peptides and conjugates thereof
|
|
HK1231400A1
(zh)
|
2014-02-11 |
2017-12-22 |
Seattle Genetics, Inc. |
蛋白质的选择性还原
|
|
IL290116B2
(en)
|
2014-02-17 |
2024-06-01 |
Seagen Inc |
Hydrophilic antibody-drug conjugates
|
|
SG11201606791YA
(en)
|
2014-03-03 |
2016-09-29 |
Academia Sinica |
Bi-specific antibodies and uses thereof
|
|
JP2017518958A
(ja)
|
2014-03-19 |
2017-07-13 |
マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルＭａｃｋａｙ Ｍｅｄｉｃａｌ Ｆｏｕｎｄａｔｉｏｎ Ｔｈｅ Ｐｒｅｓｂｙｔｅｒｉａｎ Ｃｈｕｒｃｈ Ｉｎ Ｔａｉｗａｎ Ｍａｃｋａｙ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ |
免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
|
|
CN106132434A
(zh)
*
|
2014-04-07 |
2016-11-16 |
西雅图基因公司 |
抗‑cd19抗体和抗体‑药物偶联物的稳定制剂
|
|
KR20160141727A
(ko)
*
|
2014-04-08 |
2016-12-09 |
시애틀 지네틱스, 인크. |
Cd19-항체 약물 컨쥬게이트의 최적의 주입
|
|
US9884817B2
(en)
|
2014-06-13 |
2018-02-06 |
Novartis Ag |
Auristatin derivatives and conjugates thereof
|
|
DK3160513T3
(da)
|
2014-06-30 |
2020-04-06 |
Glykos Finland Oy |
Saccharidderivat af en toksisk payload og antistofkonjugater deraf
|
|
RU2017110068A
(ru)
|
2014-09-03 |
2018-10-03 |
Иммуноджен, Инк. |
Конъюгаты, содержащие клеточносвязывающие агенты и цитотоксические агенты
|
|
JP6531166B2
(ja)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
|
KR20170053648A
(ko)
|
2014-09-11 |
2017-05-16 |
시애틀 지네틱스, 인크. |
삼차 아민-함유 약물 물질의 표적화된 전달
|
|
US20160082120A1
(en)
|
2014-09-23 |
2016-03-24 |
Genentech, Inc. |
METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
|
|
AP2017009823A0
(en)
|
2014-09-26 |
2017-03-31 |
Macrogenics Inc |
Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
|
|
MA41414A
(fr)
*
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
|
CN107406507A
(zh)
*
|
2015-02-12 |
2017-11-28 |
西雅图基因公司 |
使用cd19‑adc和长春新碱的组合疗法
|
|
ES2795818T3
(es)
|
2015-03-18 |
2020-11-24 |
Seattle Genetics Inc |
Anticuerpos CD48 y conjugados de los mismos
|
|
PT3302550T
(pt)
|
2015-05-26 |
2019-11-26 |
Morphosys Ag |
Combinação de um anticorpo anti-cd19 e de um inibidor de tirosina cinase de bruton e utilizações da mesma
|
|
CN107921144B
(zh)
*
|
2015-06-20 |
2023-11-28 |
杭州多禧生物科技有限公司 |
澳瑞他汀类似物及其与细胞结合分子的共轭偶联物
|
|
BR112017027498A2
(pt)
|
2015-06-30 |
2018-09-11 |
Seattle Genetics Inc |
anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença.
|
|
AU2016311136B2
(en)
|
2015-08-21 |
2022-02-17 |
Incyte Corporation |
Combinations and uses thereof
|
|
EP4400507A3
(en)
|
2015-09-08 |
2024-11-13 |
Waters Technologies Corporation |
Multidimensional chromatography method for analysis of antibody-drug conjugates
|
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
|
MX2018004285A
(es)
|
2015-10-08 |
2018-11-09 |
Zymeworks Inc |
Construcciones polipeptidicas de union al antigeno que comprenden cadenas ligeras kappa y lambda y usos de estas.
|
|
CA3001859A1
(en)
|
2015-10-16 |
2017-04-20 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for inhibition of lineage specific antigens
|
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
|
TWI814699B
(zh)
|
2015-12-04 |
2023-09-11 |
美商思進公司 |
四級胺化妥布賴森(tubulysin)化合物之結合物
|
|
MX2018009700A
(es)
|
2016-02-17 |
2019-01-24 |
Seattle Genetics Inc |
Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios.
|
|
WO2017160954A1
(en)
|
2016-03-15 |
2017-09-21 |
Seattle Genetics, Inc. |
Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
|
|
UA125510C2
(uk)
|
2016-03-25 |
2022-04-13 |
Сіджен Інк. |
Спосіб отримання пегильованої сполуки лікарський препарат-лінкер, де лікарським препаратом є ауристатин, та її проміжних сполук
|
|
CN109715207B
(zh)
*
|
2016-03-29 |
2023-03-31 |
南加利福尼亚大学 |
靶向癌症的嵌合抗原受体
|
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
|
LT3465214T
(lt)
|
2016-05-30 |
2021-10-11 |
Morphosys Ag |
Anti-cd19 terapijos terapinės naudos pacientams prognozavimo metodai
|
|
WO2018005519A2
(en)
|
2016-06-27 |
2018-01-04 |
The Regents Of The University Of California |
Cancer treatment combinations
|
|
MA45450B1
(fr)
|
2016-06-27 |
2021-04-30 |
Morphosys Ag |
Formulations d'anticorps anti-cd19
|
|
EP3487525A4
(en)
*
|
2016-07-22 |
2020-03-18 |
Seattle Genetics, Inc. |
COMBINATION THERAPY WITH CD19-ADC AND RCHP
|
|
SG11201900699QA
(en)
|
2016-08-09 |
2019-02-27 |
Seattle Genetics Inc |
Drug conjugates with self-stabilizing linkers having improved physiochemical properties
|
|
US20180064758A1
(en)
*
|
2016-09-05 |
2018-03-08 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
JP2019534882A
(ja)
|
2016-10-11 |
2019-12-05 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
免疫介在性療法薬を有する抗体−薬物コンジュゲート
|
|
MX2019004046A
(es)
|
2016-10-18 |
2019-08-21 |
Seattle Genetics Inc |
Administracion dirigida de inhibidores de la via de rescate de nicotinamida adenina dinucleotido.
|
|
CN109890418B
(zh)
|
2016-10-28 |
2024-03-08 |
莫佛塞斯公司 |
抗cd19抗体与bcl-2抑制剂的组合及其用途
|
|
JP7244987B2
(ja)
|
2016-12-14 |
2023-03-23 |
シージェン インコーポレイテッド |
多剤抗体薬物コンジュゲート
|
|
CN108452318B
(zh)
*
|
2017-02-17 |
2023-05-26 |
浙江特瑞思药业股份有限公司 |
靶向cd20的抗体偶联药物及其制备方法和用途
|
|
EP3589320A4
(en)
|
2017-02-28 |
2020-12-23 |
Seagen Inc. |
ANTIBODIES UNDERGOING CYSTEINE MUTATION FOR CONJUGATION
|
|
MX2019010196A
(es)
|
2017-02-28 |
2019-12-19 |
Vor Biopharma Inc |
Composiciones y métodos para la inhibición de proteínas específicas del linaje.
|
|
KR102648564B1
(ko)
|
2017-03-24 |
2024-03-19 |
씨젠 인크. |
글루쿠로니드 약물-링커의 제조 공정 및 그 중간물
|
|
AU2018256436B2
(en)
|
2017-04-19 |
2024-12-05 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
EP3615081A1
(en)
|
2017-04-27 |
2020-03-04 |
Seattle Genetics, Inc. |
Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
|
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
|
KR102344616B1
(ko)
|
2017-05-30 |
2021-12-31 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 |
항-더블코르틴-유사 키나제 1 항체 및 사용 방법
|
|
SMT202300338T1
(it)
|
2017-05-31 |
2023-11-13 |
Morphosys Ag |
Paradigma di trattamento per un trattamento combinato di anticorpo anti-cd19 e venetoclax
|
|
US11634488B2
(en)
|
2017-07-10 |
2023-04-25 |
International—Drug—Development—Biotech |
Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics
|
|
HUE066314T2
(hu)
*
|
2017-08-10 |
2024-07-28 |
Sumitomo Pharma Co Ltd |
Antitest-gyógyszer konjugátumok hemiaszterin-származékkal
|
|
EP4321523A3
(en)
*
|
2017-08-10 |
2024-04-24 |
Sumitomo Pharma Co., Ltd. |
Hemiasterlin derivatives and antibody-drug conjugates including same
|
|
CA3074524A1
(en)
*
|
2017-09-21 |
2019-03-28 |
WuXi Biologics Ireland Limited |
Novel anti-cd19 antibodies
|
|
SG11202002508XA
(en)
|
2017-09-22 |
2020-04-29 |
Wuxi Biologics Ireland Ltd |
Novel bispecific cd3/cd19 polypeptide complexes
|
|
CN111201244A
(zh)
|
2017-10-12 |
2020-05-26 |
学校法人庆应义塾 |
特异性结合到水通道蛋白3(aqp3)的细胞外域的抗aqp3单克隆抗体及其用途
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
SG11202004751TA
(en)
|
2017-12-01 |
2020-06-29 |
Seattle Genetics Inc |
Humanized anti-liv1 antibodies for the treatment of breast cancer
|
|
KR20200091901A
(ko)
|
2017-12-01 |
2020-07-31 |
시애틀 지네틱스, 인크. |
암을 치료하기 위한 cd47 항체 및 이의 용도
|
|
EP3728330A4
(en)
*
|
2017-12-23 |
2021-12-08 |
Uwell Biopharma Inc. |
PHARMACEUTICAL COMPOSITION OF CHEMICAL RECEPTOR AND ASSOCIATED PROCESS
|
|
MA51583A
(fr)
*
|
2018-01-04 |
2020-11-11 |
Avidity Biosciences Inc |
Molécules d'acide nucléique hétéroduplex et leurs utilisations
|
|
JP7273421B2
(ja)
|
2018-02-21 |
2023-05-15 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
|
|
WO2019183438A1
(en)
|
2018-03-23 |
2019-09-26 |
Seattle Genetics, Inc. |
Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
|
|
EP3796942A1
(en)
|
2018-05-23 |
2021-03-31 |
ADC Therapeutics SA |
Molecular adjuvant
|
|
TW202519270A
(zh)
|
2018-06-07 |
2025-05-16 |
美商思進公司 |
喜樹鹼結合物
|
|
TW202019487A
(zh)
|
2018-08-06 |
2020-06-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物及微管蛋白抑制劑之組合
|
|
EP3844187A1
(en)
|
2018-08-28 |
2021-07-07 |
Vor Biopharma, Inc. |
Genetically engineered hematopoietic stem cells and uses thereof
|
|
KR20200030337A
(ko)
|
2018-09-12 |
2020-03-20 |
주식회사 녹십자랩셀 |
종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
|
|
AU2019370339B2
(en)
*
|
2018-11-01 |
2024-07-11 |
Shandong New Time Pharmaceutical Co., Ltd. |
Bispecific antibody and use thereof
|
|
AU2020216486A1
(en)
*
|
2019-02-01 |
2021-08-19 |
Memorial Sloan Kettering Cancer Center |
Senolytic car-T cells targeting uPAR, a cell surface and secreted senescence biomarker
|
|
KR20210125511A
(ko)
|
2019-02-05 |
2021-10-18 |
씨젠 인크. |
항-cd228 항체 및 항체-약물 컨쥬게이트
|
|
JP7432531B2
(ja)
|
2019-02-13 |
2024-02-16 |
住友ファーマ株式会社 |
システイン残基を有するヘミアスタリン誘導体
|
|
JP7560255B2
(ja)
*
|
2019-02-13 |
2024-10-02 |
住友ファーマ株式会社 |
ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬
|
|
US12178879B2
(en)
|
2019-02-13 |
2024-12-31 |
Sumitomo Pharma Co., Ltd. |
Hemiasterlin derivative and antibody-drug conjugate thereof
|
|
WO2020213084A1
(en)
|
2019-04-17 |
2020-10-22 |
Keio University |
Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
|
|
KR20220007087A
(ko)
|
2019-05-03 |
2022-01-18 |
모르포시스 아게 |
제한된 수의 nk 세포를 갖는 환자에서의 항-cd19 치료제
|
|
US20220233709A1
(en)
|
2019-06-05 |
2022-07-28 |
Seagen Inc. |
Masked Antibody Formulations
|
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
|
CN110128551A
(zh)
*
|
2019-06-05 |
2019-08-16 |
上海科弈药业科技有限公司 |
一种针对cd19+肿瘤的多功能融合蛋白及其应用
|
|
TW202112801A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
純化遮蔽抗體之方法
|
|
AU2020318975A1
(en)
|
2019-07-22 |
2022-03-17 |
Seagen Inc. |
Humanized anti-LIV1 antibodies for the treatment of cancer
|
|
US20220347298A1
(en)
|
2019-10-04 |
2022-11-03 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
AU2020358859A1
(en)
|
2019-10-04 |
2022-05-12 |
Seagen Inc. |
Anti-PD-L1 antibodies and antibody-drug conjugates
|
|
JP7688025B2
(ja)
|
2019-10-31 |
2025-06-03 |
インサイト・コーポレイション |
抗ｃｄ１９抗体及びガンマデルタｔ細胞を含む抗腫瘍併用療法
|
|
TWI865644B
(zh)
|
2019-10-31 |
2024-12-11 |
德商莫菲西斯公司 |
用於治療白血病或淋巴瘤之抗cd19療法與來那度胺(lenalidomide)的組合
|
|
AU2020403273A1
(en)
*
|
2019-12-11 |
2022-06-30 |
Cullinan Oncology, Inc. |
Anti-CD19 antibodies and multi-specific binding proteins
|
|
CN115916816A
(zh)
*
|
2019-12-11 |
2023-04-04 |
库利南肿瘤股份有限公司 |
抗血清白蛋白抗体
|
|
WO2021178253A1
(en)
*
|
2020-03-03 |
2021-09-10 |
Systimmune, Inc. |
Anti-cd19 antibodies and methods of using and making thereof
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
CA3176248A1
(en)
|
2020-04-10 |
2021-10-14 |
Seagen Inc. |
Charge variant linkers
|
|
CA3181827A1
(en)
|
2020-06-22 |
2021-12-30 |
Morphosys Ag |
Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirp?-cd47 innate immune checkpoint
|
|
US20230295330A1
(en)
|
2020-08-04 |
2023-09-21 |
Seagen Inc. |
Anti-cd228 antibodies and antibody-drug conjugates
|
|
EP4217395A1
(en)
|
2020-09-28 |
2023-08-02 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
|
US20240262907A1
(en)
|
2020-10-06 |
2024-08-08 |
Xencor, Inc. |
Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle)
|
|
WO2022079211A1
(en)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugates
|
|
MX2023004941A
(es)
|
2020-11-08 |
2023-07-12 |
Seagen Inc |
Conjugado de anticuerpo y fármaco para terapia de combinación con inhibidor de células inmunitarias.
|
|
WO2022117799A2
(en)
|
2020-12-04 |
2022-06-09 |
Morphosys Ag |
Anti-cd19 combination therapy
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
US12030888B2
(en)
|
2021-02-24 |
2024-07-09 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
|
TW202300178A
(zh)
|
2021-03-18 |
2023-01-01 |
美商西根公司 |
內化的生物活性化合物偶聯物選擇性釋放藥物
|
|
WO2022236047A1
(en)
*
|
2021-05-07 |
2022-11-10 |
Viela Bio, Inc. |
Use of an anti-cd19 antibody to treat myasthenia gravis
|
|
WO2023288236A1
(en)
|
2021-07-14 |
2023-01-19 |
Seagen Inc. |
Antibody masking domains
|
|
EP4405387A1
(en)
|
2021-09-24 |
2024-07-31 |
Seagen Inc. |
Improved antibody masking domains
|
|
WO2023073645A1
(en)
|
2021-10-29 |
2023-05-04 |
Takeda Pharmaceutical Company Limited |
Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|
|
US20250042983A1
(en)
*
|
2021-12-10 |
2025-02-06 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Anti-lcn-2 antibodies as a treatment for eye disorders
|
|
IL315508A
(en)
|
2022-03-17 |
2024-11-01 |
Seagen Inc |
Camptothecin conjugates
|
|
KR102835682B1
(ko)
*
|
2022-06-16 |
2025-07-22 |
애브비 바이오테라퓨틱스 인크. |
항-cd19 항체-약물 접합체
|
|
KR20250052388A
(ko)
|
2022-08-17 |
2025-04-18 |
인사이트 코포레이션 |
항-cd19 항체 및 ezh2 조절제를 포함하는 요법
|
|
CN120282982A
(zh)
|
2022-09-21 |
2025-07-08 |
思进公司 |
结合cd228的抗体
|
|
WO2024097816A1
(en)
|
2022-11-03 |
2024-05-10 |
Seagen Inc. |
Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|
|
EP4634227A1
(en)
|
2022-12-13 |
2025-10-22 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
|
EP4661913A1
(en)
|
2023-02-09 |
2025-12-17 |
Beone Medicines I GmbH |
Self-stabilizing linker conjugates
|
|
AR132196A1
(es)
|
2023-03-23 |
2025-06-04 |
Beigene Switzerland Gmbh |
Conjugado bioactivo, método de preparación del mismo y uso del mismo
|
|
WO2024206884A1
(en)
|
2023-03-31 |
2024-10-03 |
AbelZeta Inc. |
Bispecific chimeric antigen receptors targeting cd20 and bcma
|
|
WO2025149947A1
(en)
|
2024-01-12 |
2025-07-17 |
Seagen Inc. |
Antibody-drug conjugates
|
|
WO2025157132A1
(en)
|
2024-01-23 |
2025-07-31 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof
|
|
WO2025163468A1
(en)
|
2024-01-30 |
2025-08-07 |
Seagen Inc. |
Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|
|
WO2025196639A1
(en)
|
2024-03-21 |
2025-09-25 |
Seagen Inc. |
Cd25 antibodies, antibody-drug conjugates, and uses thereof
|